Heterocyclic compounds as bradykinin antagonists

Details Heterocyclic compounds as bradykinin antagonists Heterocyclic compounds as bradykinin antagonists

1998-03-13

1999-12-28

Mach, D. Margaret

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514312, 514314, 546153, 546176, 546178, C07D21516, C07D21512, A61K 3147

Patent

active

060082291

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof.
More particularly, it relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which have activities as bradykinin antagonists, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human being or animals.
One object of this invention is to provide new and useful heterocyclic compounds and pharmaceutically acceptable salts thereof which possess activities as bradykinin antagonists.
Another object of this invention is to provide processes for the preparation of said compounds and salts thereof.
A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said heterocyclic compounds and pharmaceutically acceptable salts thereof.
Still further object of this invention is to provide a therapeutical method for the prevention and/or the treatment of bradykinin or its analogues mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, using said heterocyclic compounds and pharmaceutically acceptable salts thereof.


BACKGROUND ART

Some heterocyclic compounds have been known as described, for example, in EP-A-224,086, EP-A-261,539, Chemical Abstracts 90:34849g (1979), or Chemical Abstracts 97:18948c (1982). However, it is not known that said compounds have activities as bradykinin antagonists.
Heterocyclic compounds having activities as bradykinin antagonists have been known as described in EP-A-596,406, EP-A-622,361, WO-A-96/04251, WO-A-96/13485 and U.S. Pat. No. 5,212,182.


DISCLOSURE OF THE INVENTION

The object heterocyclic compounds of this invention are new and can be represented by the following general formula [I]: ##STR2## wherein A.sup.1 is lower alkylene, benzofuryl, benzoxazolyl or imidazopyridyl, each of which is substituted with substituent(s) selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkylamino and a heterocyclic group, ##STR3## in which R.sup.5 is amino, acylamino, cyano, hydroxy, hydroxyimino(lower)alkyl or acyl, ##STR4## in which R.sup.7 is hydrogen or halogen;
The object compound [I] or its salt can be prepared by processes as illustrated in the following reaction schemes.


Process 1
##STR5##


Process 2
##STR6##


Process 3
##STR7##


Process 4
##STR8## wherein R.sub.a.sup.5 is acylamino, group, lower alkanoyl, lower alkoxy(lower)alkanoyl, heterocycliccarbonyl optionally substituted with lower alkyl, or lower alkylsulfonyl, and form a heterocyclic group optionally substituted with oxo, defined above.
In the above and subsequent description of the present specification and claims, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following.
The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.
In this respect, the term "lower" in lower alkenoyl moiety, lower alkynoyl moiety, cyclo(lower)alkyl moiety, cyclo(lower)alkenyl moiety, ar(lower)alkenoyl moiety, ar(lower)alkynoyl moiety and heterocyclic(lower)alkenoyl moiety in the various definitions is intended to mean a group having 3 to 6 carbon atoms.
Suitable "halogen" may be fluorine, chlorine, bromine and iodine.
Suitable "lower alkyl" and lower alkyl moiety in the terms "heterocyclic(lower)alkyl", "lower alkylamino", "ar(lower)alkyl" and "hydroxyimino(lower)alkyl" may be straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl or the like, in which preferable one is C.sub.1 -C.sub.4 alkyl such as methyl, ethyl, propyl, isobutyl or tert-butyl.
Suitable "lower alkoxy" may be straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy

REFERENCES:
patent: 5563162 (1996-10-01), Oku et al.
patent: 5708173 (1998-01-01), Oku et al.

Affiliated with

Also associated with

Rating

Heterocyclic compounds as bradykinin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds as bradykinin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds as bradykinin antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2382675